Thank you for Subscribing to Life Science Review Weekly Brief
Jiong Ma is a senior board executive with over 25 years of expertise in investing, growing, and developing businesses, with a focus on new product launches in digital health, technology, and the new energy transition.
FREMONT, CA: Anavex Life Sciences is a clinical-stage biopharmaceutical company developing differentiated therapeutics to treat neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other CNS diseases announced the appointment of Jiong Ma, Ph.D. to its Board of Directors.
Jiong Ma is a senior board executive with over 25 years of expertise in investing, growing, and developing businesses, with a focus on new product launches in digital health, technology, and the new energy transition. Dr. Jiong Ma is and has been a Board Director of LinkinVax, Aledia, Voxel8, Lo3 Energy, Storiant, Fulham, Convey Computer (acquired by Micron Technology), mc10 (acquired by Medidata), Powervation (acquired by RHOM Semiconductor), Laser Light Engine, and Carbonite, which went public via IPO in 2011 and was subsequently acquired by OpenText in n 2019 for approximately 1.45 billion dollars.
“I am excited to welcome Ms. Ma to Anavex’s Board of Directors,” stated Christopher U Missling, Ph.D., President, and Chief Executive Officer, Anavex. “Ms. Ma brings extensive experience in innovative product launches to Anavex. I am confident she will make important contributions to our Board of Directors and towards the commercial development of ANAVEX2-73.”
Jiong Ma focused on investments in industry digitization, resource efficiency, mobility, renewable energy infrastructure, and deeptech as a Partner at Braemar Energy Ventures ($600 million AUM). She served on the firm’s investment committee. She oversaw more than 15 growth-stage investments, emphasizing new product launches, raising funds, negotiating and structuring investments, hiring management teams, and putting together boards.
“It is an honor to join Anavex’s Board of Directors,” said Ms. Ma. “With the focus on neurodegeneration and neurodevelopmental diseases, Anavex is tackling one of the biggest medical challenges that our society faces today. In addition, I am impressed with the breadth of Anavex’s pipeline. I look forward to applying my insights to advance Anavex towards its next stage of growth on the way to commercial success.”
She formerly worked at 3i, a global private equity firm with a $17 billion AUM, where she oversaw investments in Digital Health, TMT, and Cleantech at various phases. Jiong Ma held numerous key positions at Lucent Technologies and Bell Labs before joining 3i’s Venture Capital Group. Furthermore, her responsibilities included product portfolio planning, new product releases for Optical and Data Networking, research and product development, and product portfolio strategy. Jiong Ma was also a member of the founding team of Onetta, a fiber network firm. She holds a doctorate in electrical and computer engineering from the University of Colorado at Boulder and a master’s degree in electrical engineering from Worcester Polytechnic Institute. She has been named a Kauffman Fellow.